AR and prostate carcinoma: Among the many androgen variants, AR-V7, which is in absence of ligand-binding domain, and only retains the key domain for functional activation, the N-terminal domain and DNA-binding domain, has received the most attention, as it has guiding significance for doctors to management of prostate cancer (20–23).